{"database":"biostudies-literature","file_versions":[],"scores":null,"additional":{"omics_type":["Unknown"],"volume":["21(1)"],"submitter":["Yu DQ"],"pubmed_abstract":["<h4>Aims</h4>We aimed to assess the comparative efficiency and safety of the use of glyburide, metformin, and insulin in gestational diabetes mellitus (GDM).<h4>Methods</h4>We searched for randomized controlled trials that compared glyburide, metformin, and insulin in GDM. Data regarding glycemic control and neonatal safety were collected and analyzed in pairwise and network meta-analyses.<h4>Results</h4>A total of 4533 individuals from 23 trials were included. Compared with glyburide, metformin reduced 2-h postprandial blood glucose (2HPG) to a greater extent (standard mean difference (SMD) 0.18; 95% credible interval (CI) 0.01, 0.34). There were significantly lower prevalence of neonatal hypoglycemia (risk difference (RD) - 0.07; 95%CI - 0.11, - 0.02) and preeclampsia (RD - 0.03; 95%CI -"],"journal":["BMC endocrine disorders"],"pagination":["199"],"full_dataset_link":["https://www.ebi.ac.uk/biostudies/studies/S-EPMC8513183"],"repository":["biostudies-literature"],"pubmed_title":["Glycemic control and neonatal outcomes in women with gestational diabetes mellitus treated using glyburide, metformin, or insulin: a pairwise and network meta-analysis."],"pmcid":["PMC8513183"],"pubmed_authors":["Rao JP","Wang LQ","Teng XY","Jin M","Xu GX","Yu DQ","Tang LF","Xu JW","Feng C"],"additional_accession":[]},"is_claimable":false,"name":"Glycemic control and neonatal outcomes in women with gestational diabetes mellitus treated using glyburide, metformin, or insulin: a pairwise and network meta-analysis.","description":"<h4>Aims</h4>We aimed to assess the comparative efficiency and safety of the use of glyburide, metformin, and insulin in gestational diabetes mellitus (GDM).<h4>Methods</h4>We searched for randomized controlled trials that compared glyburide, metformin, and insulin in GDM. Data regarding glycemic control and neonatal safety were collected and analyzed in pairwise and network meta-analyses.<h4>Results</h4>A total of 4533 individuals from 23 trials were included. Compared with glyburide, metformin reduced 2-h postprandial blood glucose (2HPG) to a greater extent (standard mean difference (SMD) 0.18; 95% credible interval (CI) 0.01, 0.34). There were significantly lower prevalence of neonatal hypoglycemia (risk difference (RD) - 0.07; 95%CI - 0.11, - 0.02) and preeclampsia (RD - 0.03; 95%CI -","dates":{"release":"2021-01-01T00:00:00Z","publication":"2021 Oct","modification":"2025-04-20T02:06:09.254Z","creation":"2025-02-19T00:18:38.64Z"},"accession":"S-EPMC8513183","cross_references":{"pubmed":["34641848"],"doi":["10.1186/s12902-021-00865-9"]}}